Lilly and CureVac Announce Global Collaboration to Develop mRNA Cancer Vaccines
"We are excited to be collaborating with CureVac to discover what could potentially be the next frontier of cancer medicines," said
Under the terms of the agreement, CureVac will receive an upfront payment of
CureVac's proprietary RNActive technology will be used to deliver mRNA that ultimately directs the human immune system to target the encoded neoantigens. These tumor-specific neoantigens instruct the patient's existing immune system to mount a selective and potent response to eradicate the cancer.
This transaction is subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act and other customary closing conditions. Subject to the closing of this transaction, Lilly expects to incur an acquired in-process research and development charge to earnings of approximately
About Eli Lilly and Company
Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at www.lilly.com and http://newsroom.lilly.com/social-channels.
CureVac is a leading company in the field of messenger RNA (mRNA) technology with more than 17 years expertise in handling, optimizing and manufacturing this versatile molecule for medical purposes. The principle of CureVac's proprietary technology is the use of mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases. The company applies its technologies for the development of cancer therapies, prophylactic vaccines and molecular therapies.
To date, CureVac has received approximately
Lilly Forward-Looking Statement
This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about the benefits of a collaboration between Lilly and CureVac, and reflects Lilly's current beliefs. However, as with any such undertaking, there are substantial risks and uncertainties in the process of drug development and commercialization. Among other things, there can be no guarantee that Lilly will realize the expected benefits of the collaboration, or that the collaboration will yield commercially successful products. For a further discussion of these and other risks and uncertainties that could cause actual results to differ from Lilly's expectations, please see Lilly's most recent Forms 10-K and 10-Q filed with the
Lauren Zierke; email@example.com; +1-317-277-6524 (Lilly Media)
Phil Johnson; firstname.lastname@example.org; +1-317-655-6874 (Lilly Investors)
Verena Lauterbach; email@example.com; 0049-7071-9883-1756
Jason Rando; firstname.lastname@example.org; +1 212-375-2665 (CureVac PR Agency
View original content with multimedia:http://www.prnewswire.com/news-releases/lilly-and-curevac-announce-global-collaboration-to-develop-mrna-cancer-vaccines-300538729.html